Artiva Biotherapeutics views as its critical and necessary mission making cancer cell therapies available to all.
Novel technology could revolutionize production if biopharma industry can improve the quality of its manufacturing.
Gene therapy developers are advised to take a cue from how drugs were made not so long ago.
Firm is investigating hematopoietic stem cell gene therapies for Wiskott Aldrich syndrome and transfusion-dependent beta thalassemia.
Pharma 4.0 looks to be a total strategic move as biopharmaceutical manufacturing plants become ecosystems of intensified, connected operations.
A cell processing and screening system that combines microfluidics and light helped the company shave three months off development timelines for antibody-based drugs.
An expert explores new approaches to simulating processes more effectively since current computational techniques sometimes do not always take the final product into consideration.
Computer modeling can cut development time and yield bioprocesses that produce safer, better quality medicines says a leading researcher.
One day, maybe soon, patients might make their own therapeutics for their own specific disease, thus realizing the potential of personalized medicine.
A European contract manufacturer says it has accelerated its upstream bioprocessing by one third, thanks to a new intensification strategy.
Please wait while you are redirected to the right page...